ClinicalTrials.Veeva

Find clinical trials for Alzheimer's Disease in Madrid, MD

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Alzheimer Disease
Dementia
Cognitive Dysfunction
Mental Disorders
Brain Diseases
Neurodegenerative Diseases
Psychomotor Agitation

Alzheimer's Disease trials near Madrid, MD, ESP:

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndr...

Enrolling
Prodromal Alzheimer's Disease
Alzheimer's Disease
Biological: ACI-24.060 at Dose A
Biological: ACI-24.060 at Dose D

Phase 1, Phase 2

AC Immune

Madrid, Spain and 16 other locations

is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Tri...

Enrolling
Preclinical Alzheimer's Disease
Early Preclinical Alzheimer's Disease
Drug: Lecanemab
Drug: Placebo

Phase 3

Eisai
Eisai

Madrid, Spain and 111 other locations

Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elder...

Enrolling
Alzheimer's Disease (AD)
Drug: ABBV-552
Drug: Placebo for ABBV-552

Phase 2

AbbVie
AbbVie

Madrid, Spain and 63 other locations

versus (vs) placebo on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) up to Week 80 in study participants with prodromal or mild Alzheimer's...

Active, not recruiting
Alzheimer's Disease
Other: Placebo
Biological: Bepranemab

Phase 2

UCB
UCB

Madrid, Spain and 101 other locations

be from 2 clinical subgroups: mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild Alzheimer's disease...

Active, not recruiting
Alzheimer's Disease
Drug: Lecanemab 2.5 mg/kg
Drug: Lecanemab 10 mg/kg

Phase 2

Eisai
Eisai

Madrid, Spain and 168 other locations

This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determin...

Active, not recruiting
Early Alzheimer's Disease
Drug: Lecanemab
Drug: Placebo

Phase 3

Eisai
Eisai

Madrid, Spain and 246 other locations

administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's...

Enrolling
Alzheimer Disease
Drug: Placebo
Drug: ACU193

Phase 2, Phase 3

Acumen Pharmaceuticals

Madrid, Spain and 124 other locations

The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (inclu...

Enrolling
Alzheimer's Disease
Other: Placebo
Drug: GSK4527226

Phase 2

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Madrid, Spain and 103 other locations

A long-term extension study to evaluate the safety, tolerability, and efficacy of AL002 in participants with Early Alzheimer's Disease...

Enrolling
Alzheimer's Disease
Drug: AL002

Phase 2

Alector

Madrid, Spain and 26 other locations

A phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of AL002 in participants with Early Alzheimer's...

Active, not recruiting
Alzheimer Disease
Drug: Placebo
Drug: AL002

Phase 2

Alector

Madrid, Spain and 91 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems